GlassScriptPhysician profile
Gerald T Arbour
NPI 1831300607
$6,566.75
in general payments reported to CMS, 2019-2025
22 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $478 · 2021: $342 · 2022: $553 · 2023: $2,109 · 2024: $1,180 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,103 · Consulting Fee: $1,250 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,103.40 |
| Consulting Fee | $1,250.00 |
| Education | $112.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $1,432.00 | 2023-2025 | Ibsrela |
| Abbvie INC. | $1,426.41 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $642.67 | 2020-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $528.50 | 2019-2025 | Livdelzi |
| Celgene Corporation | $397.89 | 2022-2024 | Zeposia |
| Pfizer INC. | $288.05 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $260.56 | 2022-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $213.24 | 2020-2025 | Entyvio |
| Genzyme Corporation | $202.03 | 2023-2025 | |
| Micro-Tech Endoscopy USA, INC. | $192.32 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.56 | 2020-2021 | |
| Allergan, INC. | $164.34 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $127.69 | 2019 | |
| Echosens North America, INC. | $125.34 | 2024 | Fibroscan |
| Ironwood Pharmaceuticals, INC | $100.00 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $91.19 | 2019 | |
| Boston Scientific Corporation | $59.56 | 2024 | |
| Madrigal Pharmaceuticals | $49.36 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $32.22 | 2023 | |
| Phathom Pharmaceuticals, INC. | $25.23 | 2025 | Voquezna |
| Braintree Laboratories, INC. | $15.83 | 2019 | |
| Aimmune Therapeutics, INC. | $14.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Arbour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.